FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change
SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection in patients at high risk for severe complications, including in patients who are immunocompromised
https://finance.yahoo.com/news/sab-biotherapeutics-granted-fast-track-123000158.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.